USNA

USANA’s first quarter saw steady performance, with revenue flat year-over-year and a positive market reaction following results that surpassed Wall Street expectations. Management credited sequential improvements in their core nutritional business to active customer growth, particularly in China, and highlighted the impact of new product launches and investments in technology modernization. CEO Kevin Guest emphasized, “Our first quarter results reflect USANA’s continued and deliberate transformation from a single-channel direct sales business to a diversified omni-channel health and wellness platform.” Is now the time to buy USNA? Find out in our full research report (it’s free). Revenue: $250.2 million vs analyst estimates of $241 million (flat year on year, 3.8% beat) Adjusted EPS: $0.61 vs analyst estimates of $0.44 (38.6% beat) Adjusted EBITDA: $28.36 million vs analyst estimates of $22.23 million (11.3% margin, 27.6% beat) The company reconfirmed its revenue guidance for the full year of $962.5 million at the midpoint Management reiterated its full-year Adjusted EPS guidance of $2.12 at the midpoint EBITDA guidance for the full year is $105 million at the midpoint, above analyst estimates of $100.2 million Operating Margin: 5.5%, in line with the same quarter last year Market Capitalization: $321.7 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Anthony Chester Lebiedzinski (Sidoti & Company) asked about macro conditions in China and the potential impact of rising fuel prices from the Iran conflict. Chief Commercial Officer Brent L. Neidig responded that China’s consumer environment remains stable, with no material impact seen yet. Lebiedzinski (Sidoti & Company) sought more detail on the product innovation pipeline. Chief Science Officer Dr. Kathryn Armstrong confirmed over 20 products are in development, focused on women’s and children’s health, as well as leveraging channel learnings. Lebiedzinski (Sidoti & Company) inquired about HYA’s international expansion and Target launch. Neidig shared that Canadian results exceeded expectations, UK is in early stages, and Target is in rollout, with optimism f...

Image source: The Motley Fool. Wednesday, May 6, 2026 at 11 a.m. ET Chief Executive Officer — Kevin Guest Chief Commercial Officer — Brent L. Neidig Chief Science Officer — Kathryn Armstrong Chief Operating Officer — Walter Noot Chief Financial Officer — G. Douglas Hekking Investor Relations/Moderator — Andrew Masuda Need a quote from a Motley Fool analyst? Email [email protected] Kevin Guest: Thank you, Andrew, and good morning, everyone. Our first quarter results reflect USANA Health Sciences, Inc.'s continued and deliberate transformation from a single-channel direct sales business to a diversified omni-channel health and wellness platform. That evolution is the defining story of this company right now, and the progress we are making across our three business segments reinforces our confidence that this strategy will deliver sustained, compounding value over time. In our core nutritional business, we saw sequential improvement in Q1. Net sales of $204 million grew 7% sequentially, driven by active customer growth, particularly in our China market, which benefited from customer acquisition activity around the Lunar New Year. The sequential improvement is encouraging and consistent with our view that the actions we are taking to stabilize the business are beginning to take hold. These actions are organized around three clear priorities. First, we are advancing the rollout of our enhanced brand partner compensation plan, which is designed to strengthen the business opportunity and improve the productivity and retention of our distributor network. Second, we are accelerating new product launches, bringing a robust pipeline of new and upgraded formulations to market. And third, we are accelerating our technology initiatives to modernize our core systems and fundamentally improve how customers experience our brands while driving future cost efficiencies across our IT infrastructure. Taken together, we remain confident that these initiatives will continue to stabilize active customer accounts and position the core nutritional business for a return to sustainable growth. Turning to our omni-channel brands, HYA and Rise Wellness, they are expanding the aperture of what USANA Health Sciences, Inc. can be, reaching consumers in new channels and through innovative formats. HYA generated $32 million in net sales in the first quarter, with active monthly subscribers of 186 t...

Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform SALT LAKE CITY, May 05, 2026--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 4, 2026. Key Financial Results First Quarter 2026 vs. First Quarter 2025 Net sales of $250 million versus $250 million. Net earnings of $7.5 million versus $9.4 million. Diluted EPS of $0.41 as compared with $0.49. Adjusted diluted EPS(1) of $0.61 as compared with $0.73. Adjusted EBITDA(2) of $28.4 million versus $29.8 million. Core Nutritional Active Customers of 404,000 versus 459,000. Hiya Active Monthly Subscribers of 186,000 versus 224,000. Company reiterates fiscal 2026 guidance. Q1 2026 Consolidated Performance "Our first quarter 2026 results reflect USANA’s continued evolution from a single-channel direct sales business to a diversified, omnichannel health and wellness enterprise," said Kevin Guest, Chairman and Chief Executive Officer. "Our omnichannel platform is intended to provide multiple growth engines, and early progress across our three segments reinforces confidence that our strategy will deliver sustained incremental value over time. The Core Nutritional business delivered solid sequential improvement during the quarter, driven by growth in total active customers in China in addition to continued focus on accelerating our new product launch initiatives. Meanwhile, Hiya established the operational foundation for a meaningfully stronger second half of the year and Rise Wellness generated triple-digit growth as Protein Pop hit Costco shelves nationwide. "As we look ahead, the investments we are making today in product innovation, brand building, channel expansion, and technology modernization reinforce confidence in our strategic direction. These investments position us to compete effectively across the full spectrum of health-conscious consumer shopping preferences. We are committed to advancing our omnichannel strategy with urgency and discipline." Q1 2026 Segment Results Core Nutritional Hiya Health Rise Wellness Balance Sheet The Company ended the quarter with $163 million in cash and cash equivalents and $14 million of debt. As of April 4, 2026, inventory totaled $99 million, a decrease of approximately $8 million, or -7% compared to balances at year-en...

The company is undergoing a deliberate transformation from a single-channel direct sales model to a diversified omni-channel health and wellness platform. Core nutritional business growth of 7% sequentially was primarily driven by customer acquisition activity in China surrounding the Lunar New Year. Management is prioritizing a three-pillar strategy: enhancing brand partner compensation, accelerating the product launch pipeline, and modernizing technology infrastructure. The Rise Wellness segment achieved a 143% sequential sales increase, largely attributed to the rapid national launch of Protein Pop Plus in Costco. HYA's performance was impacted by elevated customer acquisition costs resulting from disruptions in the Meta advertising environment that began in 2025. Strategic insourcing of HYA manufacturing and packaging is expected to generate incremental margin efficiencies starting in 2026. Full-year 2026 net sales guidance is reaffirmed at $925 million to $1 billion, with omni-channel sales expected to exceed 20% of the total mix. HYA net sales are projected between $140 million and $155 million for the full year, supported by recent entries into Canada, the UK, and Target retail locations. Technology modernization initiatives will be funded through a combination of repurposed existing resources and operational efficiency savings. The company plans to expand Protein Pop distribution to nine additional major U.S. retailers throughout the second and third quarters of 2026. Management expects the rollout of an enhanced brand partner compensation plan to improve long-term productivity and retention within the distributor network. HYA established its first international direct-to-consumer presence with launches in Canada (January) and the United Kingdom (March). The company successfully transitioned HYA to a new ERP system and 3PL provider within a year of acquisition to improve operational scalability. Inventory and cash flow in Q1 were significantly impacted by the build-up of stock required for the national Costco launch. Management noted potential uncertainty regarding global fuel prices following the Iran conflict, though no material impact has been observed in China to date. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management stated the China...

USANA Health Sciences (USNA) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +38.64%. A quarter ago, it was expected that this nutritional supplement maker would post earnings of $0.41 per share when it actually produced earnings of $0.6, delivering a surprise of +46.34%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. USANA Health, which belongs to the Zacks Medical - Drugs industry, posted revenues of $250.22 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.83%. This compares to year-ago revenues of $249.54 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. USANA Health shares have lost about 5.5% since the beginning of the year versus the S&P 500's gain of 5.2%. While USANA Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for USANA Health was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — USANA Health Sciences Inc. (USNA) on Tuesday reported profit of $7.5 million in its first quarter. On a per-share basis, the Salt Lake City-based company said it had net income of 41 cents. Earnings, adjusted for one-time gains and costs, were 61 cents per share. The nutritional supplement maker posted revenue of $250.2 million in the period. USANA Health expects full-year earnings in the range of $1.95 to $2.29 per share, with revenue in the range of $925 million to $1 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on USNA at https://www.zacks.com/ap/USNA

Health and wellness products company USANA Health Sciences (NYSE:USNA) will be reporting results this Tuesday after market close. Here’s what to look for. USANA met analysts’ revenue expectations last quarter, reporting revenues of $226.2 million, up 5.9% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS and EBITDA estimates. Is USANA a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting USANA’s revenue to decline 3.4% year on year, a reversal from the 9.5% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. USANA has missed Wall Street’s revenue estimates multiple times over the last two years. Looking at USANA’s peers in the consumer staples segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Estée Lauder delivered year-on-year revenue growth of 4.6%, meeting analysts’ expectations, and Vita Coco reported revenues up 37.3%, topping estimates by 20.5%. Vita Coco traded up 27.8% following the results. Read our full analysis of Estée Lauder’s results here and Vita Coco’s results here. There has been positive sentiment among investors in the consumer staples segment, with share prices up 2.8% on average over the last month. USANA is up 10.2% during the same time and is heading into earnings with an average analyst price target of $39 (compared to the current share price of $19.32). ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable. These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.

SALT LAKE CITY, April 15, 2026--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2026 results will be released after the close of market on Tuesday, May 5, 2026. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, May 6, 2026 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Brand Partners and Preferred Customers across 25 global markets. More information on USANA can be found at www.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company and a 100% interest in Rise Wellness. Hiya and Rise Wellness offer a variety of clean-label health products. More information on Hiya can be found at www.hiyahealth.com. More information on Rise Wellness can be found on www.risebar.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260415942776/en/ Contacts Investor contact: Andrew Masuda Investor Relations (801) 954-7201 [email protected]

Pacira BioSciences PCRX reported fourth-quarter 2025 adjusted earnings of 57 cents per share, which missed the Zacks Consensus Estimate of 85 cents, on account of lower-than-expected product revenues and heightened operating expenses. The company had reported adjusted earnings of 91 cents per share in the year-ago quarter. Total revenues amounted to $196.9 million, which increased 5% year over year. The reported figure missed the Zacks Consensus Estimate of $199 million. The investors were disappointed by the poor performance, following which the stock declined 5.7% during the after-market hours on Thursday. Pacira BioSciences’ top line comprises product sales and royalty revenues. The company recognizes product revenues from the sales of its three marketed drugs — Exparel, Zilretta and iovera. Exparel’s net product sales were $155.8 million, which increased 5% from the year-ago quarter’s figure, driven by a volume growth of approximately 7%, which was partially offset by a shift in vial mix and price discounts. The reported figure beat the Zacks Consensus Estimate of $154.6 million. Exparel (bupivacaine liposome injectable suspension) is indicated in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal. Zilretta net product sales came in at $33 million, which was relatively flat year over year. The reported figure missed the Zacks Consensus Estimate of $34.4 million. In the past six months, shares of Pacira BioSciences have lost 16.4% against the industry’s 23.1% growth. Image Source: Zacks Investment Research Net product sales of iovera were $7 million, up 8% from the year-ago quarter. The figure marginally missed the Zacks Consensus Estimate of $7.3 million. Pacira BioSciences generated revenues of $1.1 million from the sales of bupivacaine liposome injectable suspension to third-party licenses in the fourth quarter compared to none in the year-ago period. The company did not record any royalty revenues in the reported quarter or the year-ago quarter. Research and development (R&D) expenses (excluding stock-based compensation and key employee holdback) came in at $34.4 million, up 56% from the year-ago quarter. The m...

Catalyst Pharmaceuticals CPRX reported adjusted earnings of 68 cents per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of 42 cents. The company had recorded adjusted earnings of 70 cents in the year-ago quarter. Total revenues, the majority of which comprised product revenues, amounted to $152.6 million in the reported quarter, representing growth of 8% year over year. The recorded figure also surpassed the Zacks Consensus Estimate of $140 million. Catalyst Pharmaceuticals’ top line primarily comprised revenues from the sale of Firdapse, the first approved drug for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and the epilepsy drug Fycompa (perampanel) CIII. Revenues generated from the sale of the newly launched muscle disease drug, Agamree (vamorolone), also contributed to the top line. Firdapse generated sales worth $97.6 million in the reported quarter, up 18% year over year, driven by organic sales growth. The reported figure beat the Zacks Consensus Estimate of $96.4 million as well as our estimate of $95.8 million. The drug has been witnessing strong demand, increasing prescription rates from LEMS patients and continued diagnosis of new LEMS patients. In 2023, Catalyst Pharmaceuticals acquired exclusive rights to manufacture and supply Agamree from Santhera Pharmaceuticals through a licensing agreement. In late 2023, the FDA approved Agamree for treating Duchenne Muscular Dystrophy in patients aged two years and older, which gave the company a third approved product. The drug was commercially launched in the United States in the middle of March 2024. In the reported quarter, Agamree generated revenues worth $35.3 million, up 68% year over year. The reported figure beat the Zacks Consensus Estimate of $31.3 million and our estimate of $33 million. In the past six months, shares of CPRX have gained 23.1% against the industry’s 1.1% decline. Image Source: Zacks Investment Research In 2023, Catalyst Pharmaceuticals acquired the U.S. rights for Fycompa (perampanel) CIII from Eisai Co., Ltd. This acquisition diversified the company’s portfolio by adding a commercial-stage epilepsy asset. Catalyst Pharmaceuticals started recording sales of Fycompa in 2023. Fycompa generated net product revenues of $19.6 million, down significantly year over year, as tablet generics began hitting the market in May 2025 following the exp...

Acadia Pharmaceuticals ACAD reported fourth-quarter 2025 earnings per share (EPS) of 16 cents (excluding tax benefit), which beat the Zacks Consensus Estimate of 12 cents. In the year-ago quarter, the company had reported adjusted EPS of 17 cents. Including the tax benefit recognized from a one-time impact of the One Big Beautiful Bill Act, the company reported EPS of $1.60 for the fourth quarter of 2025 compared with EPS of 86 cents in the year-ago quarter. In the fourth quarter, Acadia recorded total revenues of $284 million, which missed the Zacks Consensus Estimate of $293 million. ACAD’s net product revenues comprise sales of its two marketed products, Nuplazid (pimavanserin) and Daybue (trofinetide). Acadia’s first drug, Nuplazid, is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACAD’s second product, Daybue, received approval in 2023 for treating Rett syndrome in adult and pediatric patients aged two years and older. The drug was launched in the United States in April 2023. Total revenues increased 9% year over year, driven by contributions from Daybue and continued growth in Nuplazid's market share. In the past six months, shares of Acadia have lost 6% against the industry’s 23% growth. Image Source: Zacks Investment Research Revenues from Nuplazid increased 7% year over year to $174.4 million in the fourth quarter of 2025, driven primarily by volume growth. Nuplazid sales missed the Zacks Consensus Estimate of $184.1 million. Daybue recorded net product sales of $109.6 million in the reported quarter, up 13% year over year, driven by the growth in the drug’s unit sales as Acadia shipped to more unique patients. The reported figure was a tad higher than the Zacks Consensus Estimate of $108.4 million. Research and development (R&D) expenses were $84.8 million, down 16% year over year, due to a $28 million upfront business development payment for ACP-711 that was made in the year-ago quarter to Saniona. Selling, general and administrative (SG&A) expenses were $155.6 million, up 20% year over year, owing to increased marketing investments to support Nuplazid and Daybue field expansion and marketing costs. Acadia had cash, cash equivalents and investments worth $820 million as of Dec. 31, 2025, compared with $847 million as of Sept. 30, 2025. In 2025, Acadia recorded total r...